Researchers have identified a potential vulnerability in glioblastoma, one of the brain's most aggressive and lethal cancers. Scientists discovered that blocking a protein called SET can prevent tumor formation in laboratory models and sensitize cancer cells to radiation therapy by reactivating a suppressed enzyme called PP2A.
Glioblastoma multiforme accounts for roughly 45 percent of all malignant primary brain tumors in adults. Patients typically survive only 14 to 15 months after diagnosis despite aggressive treatment combining surgery, radiation, and chemotherapy. The disease's resistance to existing therapies makes it one of oncology's most difficult challenges.
The new research targets a fundamental mechanism cancer cells use to survive. SET protein normally functions as a regulator that keeps PP2A enzyme activity in check. In glioblastoma cells, SET becomes overactive, effectively silencing PP2A. This suppression allows cancer cells to evade the normal cellular processes that would otherwise trigger their death or halt their growth.
The research team, whose work appears in preclinical models, demonstrated two distinct therapeutic angles. First, directly blocking SET protein prevented tumors from forming altogether in experimental systems. Second, targeting related proteins that work alongside SET made existing cancer cells significantly more vulnerable to radiation therapy, a standard treatment glioblastoma patients already receive.
This two-pronged approach addresses a core survival strategy glioblastoma uses. By restoring PP2A activity, researchers essentially restore cellular safeguards that cancer cells have corrupted. PP2A functions as a tumor suppressor, regulating multiple pathways that control cell division, cell death, and DNA repair. When active, it acts as a brake on uncontrolled growth.
The preclinical findings open a pathway toward combination therapy. Rather than replacing existing treatments, this approach could enhance them. Combining SET inhibition or related protein targeting with standard radiation therapy might overcome the resistance that makes glioblastoma so deadly in clinical practice.
However, significant hurdles remain before this strategy reaches patients. Preclinical models, while valuable for identifying mechanisms and testing hypotheses, do not always translate to human biology. The blood-brain barrier presents a particular challenge for brain cancer drugs. This biological barrier blocks most large molecules and many small molecules from entering brain tissue, meaning any therapeutic agent must be specifically designed to cross it.
Safety represents another concern. PP2A acts throughout the body, not just in brain tumors. Broadly activating this enzyme or broadly blocking SET could trigger unwanted effects in healthy tissues. Researchers must identify whether they can selectively target glioblastoma cells while sparing normal brain tissue.
The team's next steps involve moving toward human testing. This typically requires additional laboratory work to identify lead compounds, animal studies to assess safety and dosing, and regulatory approval before first-in-human trials can begin. That progression typically takes several years minimum.
Glioblastoma's poor prognosis creates urgency. Any approach showing promise in preclinical models warrants rapid but rigorous development. This SET-PP2A axis discovery adds a new target to the limited arsenal oncologists currently possess for this devastating disease.